Connexin-43 and Duchenne heart problems: a new target to protect the heart in DMD
Official title: Connexin 43: a new player in Duchenne muscular dystrophy associated cardiomyopathy
Funded at Rutgers Biomedical and Health Sciences · NIH-11335741 · Data updated 2026-11-12
Researchers are studying whether a heart protein called Connexin-43 can be adjusted to help people with Duchenne muscular dystrophy avoid dangerous heart problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project start | July 15, 2024 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $639,883 |
| NIH project number | 5R01HL171094-03 |
| Project ID | NIH-11335741 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are people with Duchenne muscular dystrophy who are at risk for or experiencing cardiomyopathy.
✕Less likely to help
Patients without DMD or without heart involvement may not benefit from this research.
What this research studies
Duchenne muscular dystrophy often leads to serious heart disease. This project looks at whether changes in a heart cell protein, Connexin-43, contribute to faulty heart rhythm and scarring in people with DMD. The scientists propose that a damaged microtubule structure connects dystrophin loss to Connexin-43 problems and that fixing Connexin-43’s state could reduce harmful heart remodeling. The work will combine laboratory experiments to understand the mechanism and test potential drug targets that could protect heart function in DMD patients.
Why it matters
Potential benefit: If successful, this research could point to new ways to protect the heart in people with DMD, potentially reducing arrhythmias and heart failure.
How similar studies have gone: Similar approaches have shown that targeting gap junction proteins can influence heart health in disease models, with promising but early results.
Where this research is happening
-
Rutgers Biomedical and Health Sciences
Newark, United States Active
Researchers
- Principal investigator: Fraidenraich, Diego — Rutgers Biomedical and Health Sciences
- Study coordinator: Fraidenraich, Diego
Related research
Other NIH-funded projects on the same topics.
-
How immune cells affect the heart in Duchenne muscular dystrophy
This work looks at how immune cells called macrophages contribute to heart damage in people with Duchenne muscular dystrophy.
-
3D printed human heart model for Duchenne muscular dystrophy (DMD) cardiomyopathy progression
A patient-friendly 3D-printed heart model using stem cells and gene editing helps study how DMD affects the heart over time and tests potential therapies.
-
Predicting heart disease progression in Duchenne and Becker muscular dystrophy
This project will look for blood tests and heart-imaging signs that predict how heart disease will progress in people with Duchenne or Becker muscular dystrophy and in genetic carriers.
-
Investigating Connexin 43's role in heart issues related to Duchenne muscular dystrophy
This study is looking at how a protein called Connexin 43 affects heart health in people with Duchenne muscular dystrophy, with the goal of finding new ways to help prevent heart problems like arrhythmias and heart failure.
-
Understanding heart problems in Duchenne and Becker muscular dystrophy
This study is looking at heart problems that can happen in people with Duchenne and Becker muscular dystrophy to find better ways to check heart health and track how the disease changes over time, which will help improve treatments and future drug trials for those affected.
-
New treatment for heart failure in Duchenne muscular dystrophy patients
This study is testing a new under-the-skin treatment for heart problems caused by Duchenne muscular dystrophy (DMD) to see if it can help improve heart function and possibly help patients live longer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.